You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Efficacy of a trivalent influenza vaccine against seasonal strains and against 2009 pandemic H1N1: A randomized, placebo-controlled trial
|
|---|---|
| Published in |
Vaccine, August 2016
|
| DOI | 10.1016/j.vaccine.2016.08.038 |
| Pubmed ID | |
| Authors |
William J.H. Mcbride, Walter P. Abhayaratna, Ian Barr, Robert Booy, Jonathan Carapetis, Simon Carson, Ferdinandus De Looze, Rod Ellis-Pegler, Leon Heron, Jeff Karrasch, Helen Marshall, Jodie Mcvernon, Terry Nolan, William Rawlinson, Jim Reid, Peter Richmond, Sepehr Shakib, Russell L. Basser, Gunter F. Hartel, Michael H. Lai, Steven Rockman, Michael E. Greenberg |
| Abstract |
Before pandemic H1N1 vaccines were available, the potential benefit of existing seasonal trivalent inactivated influenza vaccines (IIV3s) against influenza due to the 2009 pandemic H1N1 influenza strain was investigated, with conflicting results. This study assessed the efficacy of seasonal IIV3s against influenza due to 2008 and 2009 seasonal influenza strains and against the 2009 pandemic H1N1 strain. This observer-blind, randomized, placebo-controlled study enrolled adults aged 18-64years during 2008 and 2009 in Australia and New Zealand. Participants were randomized 2:1 to receive IIV3 or placebo. The primary objective was to demonstrate the efficacy of IIV3 against laboratory-confirmed influenza. Participants reporting an influenza-like illness during the period from 14days after vaccination until 30 November of each study year were tested for influenza by real-time reverse transcription polymerase chain reaction. Over a study period of 2years, 15,044 participants were enrolled (mean age±standard deviation: 35.5±14.7years; 54.4% female). Vaccine efficacy of the 2008 and 2009 IIV3s against influenza due to any strain was 42% (95% confidence interval [CI]: 30%, 52%), whereas vaccine efficacy against influenza due to the vaccine-matched strains was 60% (95% CI: 44%, 72%). Vaccine efficacy of the 2009 IIV3 against influenza due to the 2009 pandemic H1N1 strain was 38% (95% CI: 19%, 53%). No vaccine-related deaths or serious adverse events were reported. Solicited local and systemic adverse events were more frequent in IIV3 recipients than placebo recipients (local: IIV3 74.6% vs placebo 20.4%, p<0.001; systemic: IIV3 46.6% vs placebo 39.1%, p<0.001). The 2008 and 2009 IIV3s were efficacious against influenza due to seasonal influenza strains and the 2009 IIV3 demonstrated moderate efficacy against influenza due to the 2009 pandemic H1N1 strain. Funded by CSL Limited, ClinicalTrials.gov identifier NCT00562484. |
X Demographics
The data shown below were collected from the profiles of 15 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 3 | 20% |
| United States | 1 | 7% |
| China | 1 | 7% |
| Canada | 1 | 7% |
| Unknown | 9 | 60% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 13 | 87% |
| Practitioners (doctors, other healthcare professionals) | 1 | 7% |
| Scientists | 1 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 47 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 1 | 2% |
| Unknown | 46 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 6 | 13% |
| Student > Master | 4 | 9% |
| Researcher | 4 | 9% |
| Other | 3 | 6% |
| Professor | 3 | 6% |
| Other | 8 | 17% |
| Unknown | 19 | 40% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 21% |
| Nursing and Health Professions | 5 | 11% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Immunology and Microbiology | 2 | 4% |
| Computer Science | 2 | 4% |
| Other | 7 | 15% |
| Unknown | 19 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 February 2022.
All research outputs
#3,545,175
of 25,411,814 outputs
Outputs from Vaccine
#3,087
of 16,526 outputs
Outputs of similar age
#58,115
of 349,069 outputs
Outputs of similar age from Vaccine
#43
of 176 outputs
Altmetric has tracked 25,411,814 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 16,526 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 17.8. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 349,069 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 176 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.